Cargando…

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses

INTRODUCTION: The objective of this review was to conduct a systematic review with meta-analysis and Bayesian mixed treatment comparisons (MTC) evaluating the impact of biologics on non-Psoriasis Area and Severity Index (PASI) health outcomes in patients with moderate-to-severe plaque psoriasis. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baker, Erica L., Coleman, Craig I., Reinhart, Kurt M., Phung, Olivia J., Kugelman, Lisa, Chen, Wendy, White, C. Michael, Mamolo, Carla M., Cappelleri, Joseph C., Baker, William L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare Communications 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3510417/ https://www.ncbi.nlm.nih.gov/pubmed/23205332 http://dx.doi.org/10.1007/s13555-012-0009-3

Ejemplares similares

The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain
por: Maravilla-Herrera, Paulina, et al.
Publicado: (2023)

Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response
por: Sawyer, L.M., et al.
Publicado: (2018)

PASI AND PQOL-12 SCORE IN PSORIASIS: IS THERE ANY CORRELATION?
por: Shankar, Vikas, et al.
Publicado: (2011)

The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
por: Papp, Kim A., et al.
Publicado: (2021)

Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
por: Sawyer, Laura M., et al.
Publicado: (2019)

Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study
por: Valenzuela, F., et al.
Publicado: (2016)

Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review
por: Sobieraj, Diana M, et al.
Publicado: (2013)

Is Clear Always Clear? Comparison of Psoriasis Area and Severity Index (PASI) and the Physician’s Global Assessment (PGA) in Psoriasis Clearance
por: Wu, Albert G., et al.
Publicado: (2020)

Association Between Short-Term PASI90 Achievement and Drug Survival of Biologics in Patients with Psoriasis
por: Choi, Sungjun, et al.
Publicado: (2022)

Psoriasis Area and Severity Index (PASI) Objectivisation by Flow Cytometry Analysis of Major Lymphocytes Subsets
por: Zecevic-Pasic, Lamija, et al.
Publicado: (2023)

Both Educational Lectures and Reference Photographs Are Necessary to Improve the Accuracy and Reliability of Psoriasis Area and Severity Index (PASI) Assessment: Results from Korean Nation-Wide PASI Educational Workshop
por: Choi, Chong Won, et al.
Publicado: (2018)

PASI studies new states of matter
Publicado: (2002)

PASI studies new states of matter
por: Rafelski, Johann
Publicado: (2002)

Glycomics@ExPASy: Bridging the Gap
por: Mariethoz, Julien, et al.
Publicado: (2018)

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
por: Griffiths, C.E.M., et al.
Publicado: (2016)

ExPASy: SIB bioinformatics resource portal
por: Artimo, Panu, et al.
Publicado: (2012)

Impact of Risankizumab on PASI90 and DLQI0/1 Duration in Moderate-to-Severe Psoriasis: A Post Hoc Analysis of Four Phase 3 Clinical Trials
por: Lebwohl, Mark G., et al.
Publicado: (2021)

The effect of moving cupping on psoriasis vulgaris and its influence on PASI score: A protocol for systematic review and meta-analysis
por: Yunbo, Wu, et al.
Publicado: (2021)

A multi-item Physician Global Assessment scale to assess psoriasis disease severity: validation based on four phase III tofacitinib studies
por: Callis Duffin, Kristina, et al.
Publicado: (2019)

Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
por: Lopes, Nilcéia, et al.
Publicado: (2019)

PASI: A novel pathway method to identify delicate group effects
por: Jaakkola, Maria K., et al.
Publicado: (2018)

Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients
por: Hägg, David, et al.
Publicado: (2017)

Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment()
por: da Silva, Maria Flávia Pereira, et al.
Publicado: (2013)

The experience of pain and redness in patients with moderate to severe plaque psoriasis
por: Martin, Mona L., et al.
Publicado: (2015)

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
por: Hendrix, Nathaniel, et al.
Publicado: (2018)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

The Impact of Ramadan Fasting on the Reduction of PASI Score, in Moderate-To-Severe Psoriatic Patients: A Real-Life Multicenter Study
por: Damiani, Giovanni, et al.
Publicado: (2019)

Automated, computer-guided PASI measurements by digital image analysis versus conventional physicians’ PASI calculations: study protocol for a comparative, single-centre, observational study
por: Fink, Christine, et al.
Publicado: (2018)

Le PASI étudie de nouveaux états de la matière
Publicado: (2002)

Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?
por: Kirsten, Natalia, et al.
Publicado: (2021)

Comparing Meta-Analyses with ChatGPT in the Evaluation of the Effectiveness and Tolerance of Systemic Therapies in Moderate-to-Severe Plaque Psoriasis
por: Lam Hoai, Xuân-Lan, et al.
Publicado: (2023)

Moderate and severe plaque psoriasis: cost-of-illness study in Italy
por: Colombo, GL, et al.
Publicado: (2008)

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Ren, Vicky, et al.
Publicado: (2013)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
por: Sekhon, Sahil, et al.
Publicado: (2017)

Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2020)

Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis
por: Timmermann, Stine, et al.
Publicado: (2019)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
por: Light, Jeremy G, et al.
Publicado: (2021)

Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
por: Blair, Hannah A.
Publicado: (2021)

Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
por: Odnopozova, Liudmila, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4n82cm6jamre6q67sfnibvq8g6